FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients
Portfolio Pulse from Vandana Singh
The FDA has approved Glaukos Corporation's iDose TR, an eye implant for treating intraocular pressure in glaucoma patients. The approval is based on positive Phase 3 trial results. Glaukos plans to start commercial launch in early 2024 with a set price of $13,950 per dose. The company also reaffirmed its 2023 sales guidance and provided a preliminary 2024 sales guidance, which is above consensus estimates. GKOS shares rose 7.58% in premarket trading.
December 14, 2023 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Glaukos Corporation received FDA approval for its iDose TR eye implant, with commercial launch planned for Q1 2024 and a price of $13,950 per dose. The company reaffirmed its 2023 sales guidance and provided a higher-than-consensus 2024 sales guidance.
The FDA approval of iDose TR is a significant positive catalyst for Glaukos, likely to increase investor confidence and drive stock prices up in the short term. The premarket share price increase of 7.58% reflects immediate positive investor sentiment. The reaffirmed 2023 guidance and higher-than-expected 2024 sales guidance further support the positive outlook for the company.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100